Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06283121 | A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer | not yet recruiting | Phase 2 | 30 | China Medical University, ChinaOTHER | 0 | Feb 29, 2024 | clinicaltrials |
| NCT01935778 | Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPH | recruiting | Phase 3 | 286 | Asan Medical CenterOTHER | 1 | Feb 28, 2024 |
| clinicaltrials |
| NCT03950271 | SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma | active not recruiting | Phase 2 | 25 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06228963 | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma | recruiting | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06242613 | National Multicenter Cohort Study of Robot-Assisted Gastrectomy Versus Laparoscopy in Gastric Cancer(ROBOTAG) | enrolling by invitation | — | 400 | Hospital Universitario de Gran Canaria Doctor NegrínOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT06238167 | Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC | not yet recruiting | Phase 2 | 40 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Feb 2, 2024 | clinicaltrials |
| NCT06229197 | Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer | not yet recruiting | N/A | 176 | Sichuan UniversityOTHER | 0 | Jan 29, 2024 | clinicaltrials |
| NCT05918094 | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06213519 | HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis | not yet recruiting | Phase 2 | 69 | Sichuan UniversityOTHER | 0 | Jan 19, 2024 | clinicaltrials |
| NCT05140746 | Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT06158919 | A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer(G/GEJ cancer) | recruiting | N/A | 58 | Fudan UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05561504 | Helicobacter Pylori Local Prevalence and Antibiotic Resistance(HelicoPTER) | recruiting | — | 20,000 | Technical University of MunichOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 60 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT01678027 | Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication | active not recruiting | Phase 3 | 1,838 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06010862 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors | recruiting | Phase 1 | 36 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Nov 8, 2023 | clinicaltrials |
| NCT06121700 | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G) | recruiting | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Nov 8, 2023 | clinicaltrials |
| NCT05494060 | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma(EXPLORING) | recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT06115629 | Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial(SARONG-II) | not yet recruiting | Phase 3 | 952 | University of Dublin, Trinity CollegeOTHER | 5 | Nov 3, 2023 | clinicaltrials |
| NCT06102759 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102772 | Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT06102785 | Fruquintinib Combined With TAS102 for Advanced Gastric Cancer | recruiting | — | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05551416 | The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer | recruiting | — | 1,200 | EDUARDO ALBENIZOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06094868 | Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Oct 23, 2023 | clinicaltrials |
| NCT01133951 | Helicobacter Pylori Eradication to Prevent Gastric Cancer | active not recruiting | N/A | 3,000 | Jie-Jun WangOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05602935 | Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study | active not recruiting | Phase 2 | 29 | The Second Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT06035250 | AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy | recruiting | — | 200 | Chinese Academy of SciencesOTHER_GOV | 2 | Sep 28, 2023 | clinicaltrials |
| NCT06042998 | A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer(CLASS14) | recruiting | N/A | 588 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | recruiting | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04611997 | IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 240 | Fujian Medical UniversityOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT05318794 | Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer(SPECTRA) | not yet recruiting | Phase 2 | 20 | Imperial College LondonOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT06028724 | A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)(POPCORN) | recruiting | — | 782 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05264896 | Perioperative FLOT vs Adjuvant XELOX for CA Stomach | recruiting | Phase 3 | 110 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05956847 | The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric | recruiting | — | 1,000 | Xijing HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05914610 | Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 3 | 100 | Fujian Medical UniversityOTHER | 0 | Aug 25, 2023 | clinicaltrials |
| NCT05978882 | Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Using Fluorescence (SENORITA4) | not yet recruiting | N/A | 203 | National Cancer Center, KoreaOTHER_GOV | 1 | Aug 7, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05959226 | Effect of Exercise and Enteral Nutrition on Survival(ENERGY) | not yet recruiting | N/A | 960 | The First Hospital of Jilin UniversityOTHER | 0 | Jul 25, 2023 | clinicaltrials |
| NCT05934058 | Genomic and Dietary Aspects in Gastric Cancer Risk(GenoStoP) | not yet recruiting | — | 383,980 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT03347162 | Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer | active not recruiting | — | 1,000 | Rigshospitalet, DenmarkOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT04519151 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | recruiting | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05890339 | Laparoscopic Proximal Gastrectomy With Double-flap Technique Versus Laparoscopic Total Gastrectomy With Roux-en-Y Reconstruction for Proximal Early Gastric Cancer | not yet recruiting | N/A | 216 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | active not recruiting | Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05640609 | Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer | recruiting | Phase 1 / Phase 2 | 57 | West China HospitalOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05687357 | Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma | recruiting | Phase 2 | 140 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Feb 29, 2024source: clinicaltrials